RegulationBreakthrough Therapy (United States), Orphan Drug (United States), Orphan Drug (European Union), PRIME (European Union), Rare Pediatric Disease (United States)

Structure/Sequence

Molecular FormulaC21H20FN3O4

InChIKeyGKGRZLGAQZPEHO-UHFFFAOYSA-N

CAS Registry496054-87-6

Clinical Trials associated with Radiprodil

JPRN-jRCT2041260070

/ RecruitingPhase 3

A Multinational, Multicenter Study With an Open-Label Phase 1b and a Randomized, Double-Blind, Placebo-Controlled Phase 3 Followed by an Open-Label Extension to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of Radiprodil in Participants With GRIN-Related Neurodevelopmental Disorder

Start Date01 Jun 2026

Sponsor / Collaborator

GRIN Therapeutics, Inc.

NCT07457229

/ RecruitingPhase 1

Phase 1, Open-Label Study to Assess the Pharmacokinetics, Safety, and Tolerability of Radiprodil in Hepatically Impaired Participants

This Phase 1, open-label study will evaluate the pharmacokinetics (PK), safety, and tolerability of a single oral dose of radiprodil in adults with varying degrees of hepatic impairment compared with healthy participants. Radiprodil is being developed as a potential treatment for GRIN-related neurodevelopmental disorders, tuberous sclerosis complex, and focal cortical dysplasia.
Approximately 40 adults aged 18 to 75 years will be enrolled into five cohorts based on liver function (mild, moderate, or severe hepatic impairment) or healthy status. Participants will receive a single 15 mg oral dose of radiprodil and remain in the clinical research unit for intensive PK and safety monitoring through Day 6.
The primary objective is to characterize the PK profile of radiprodil in participants with hepatic impairment compared with healthy participants. Safety and tolerability will also be assessed. Results from this study will help determine whether dose adjustments are needed in individuals with impaired liver function.

Start Date03 Mar 2026

Sponsor / Collaborator

GRIN Therapeutics, Inc.

NCT06975605

/ CompletedPhase 1

Phase 1, Open-label, 3-period Study to Evaluate Drug-Drug Interaction Potential of Radiprodil With Cocktail Probes Representative of CYP3A4, CYP2C9, CYP2C19, P-gp and BCRP in Healthy Adult Subjects

This is a Phase 1, open-label, 3-period study to determine radiprodil's potential to act as a perpetrator of cytochrome P-450 (CYP) metabolic pathways and transporter pathways. The study will evaluate the pharmacokinetics (PK) and safety effects of co-administration of radiprodil with oral midazolam, rosuvastatin, warfarin, digoxin, and omeprazole in healthy adult subjects. The study will be conducted in 1 cohort of healthy adult participants only.

Start Date20 May 2025

Sponsor / Collaborator

GRIN Therapeutics, Inc.

[+1]

100 Clinical Results associated with Radiprodil

100 Translational Medicine associated with Radiprodil

100 Patents (Medical) associated with Radiprodil

Literatures (Medical) associated with Radiprodil

05 Mar 2026·BRAIN

Inhibition of GluN2B-containing N -methyl- D- aspartate receptors by radiprodil

Article

Author: Low, Chian-Ming ; Perszyk, Riley E ; Kim, Sukhan ; Zhang, Jing ; Xing, Hao ; Traynelis, John F ; Liang, Steven H ; Nitsche, Karolina ; Chen, Jiahui ; Roache, Steve ; Won, Sehoon ; Diaz, Eva S ; Song, Rui ; Yuan, Hongjie ; McDaniels, Ellington D ; Regan, Michael C ; Raymond, Christopher S ; Rong, Jian ; Myers, Scott J ; Traynelis, Stephen F ; Furukawa, Hiro ; Zhang, Lu ; Simorowski, Noriko ; Roche, Katherine W ; Chaudhary, Ahmad F ; Banke, Tue G ; Zhou, Xin

Abstract:

N-methyl-D-aspartate (NMDA) receptors mediate a slow, Ca2+-permeable component of excitatory synaptic transmission in the brain and participate in neuronal development and synaptic plasticity. Most NMDA receptors are tetrameric assemblies of two GluN1 and two GluN2 subunits encoded by five genes (GRIN1 and GRIN2A–GRIN2D), which produce GluN1 and GluN2A–GluN2D subunits. NMDA receptors that contain the GluN2B subunit have unique pharmacological properties, being inhibited by multiple structurally distinct series of biaryl compounds with high potency and selectivity. These agents are of considerable therapeutic interest, given the numerous roles that GluN2B-containing NMDA receptors play in normal brain function and pathological situations.Among GluN2B-selective negative allosteric modulators, radiprodil inhibits NMDA receptors that contain GluN2B with high potency and selectivity and appears to be safe in humans. Here, we evaluate the structural determinants of radiprodil binding to the heterodimeric GluN1–GluN2B amino terminal domain by X-ray crystallography and explore the molecular mechanism of inhibition. A large number of de novo variants have been identified in the GRIN gene family in patients with various neurological and neuropsychiatric conditions, including autism, intellectual disability, epilepsy, language disorders and movement disorders. We show that radiprodil is an effective antagonist at >80% of human disease-associated GRIN1 and GRIN2B missense variants tested in vitro (22/27, equally or more effective as wild-type receptors), including variants in the pore-forming region, linker regions and elsewhere that uniformly increase NMDA receptor-mediated charge transfer. We show that radiprodil blocks synaptic GluN2B receptors in brain slices acutely isolated from a knock-in mouse line harbouring the gain-of-function variant GluN2B-Ser810Arg associated with early-onset epileptic encephalopathy and intractable seizures in patients. In addition, radiprodil delays the onset of seizures (458 ± 90 s, versus 207 ± 23 s in the vehicle group) in response to in vivo administration of the chemoconvulsant pentylenetetrazole.These data support the potential utility of GluN2B-selective antagonists, such as radiprodil, for clinical treatments of neurological conditions where clinical aetiologies might involve increased current mediated by GluN2B-containing NMDA receptors.

01 Jan 2026·ACTA PHARMACOLOGICA SINICA

New advances in small molecule drugs targeting NMDA receptors

Review

Author: Zeng, Yue ; Zhu, Qian-Wen ; Wang, Hai-Ying ; Gao, Zhao-Bing ; Qu, Zhi-Yan ; Zhou, Yu

N-methyl-D-aspartate (NMDA) receptors are glutamate-gated ion channels that are ubiquitously expressed throughout the central nervous system (CNS) and serve as crucial mediators of neural development and synaptic plasticity. Dysregulation of NMDA receptor activity has been implicated in a wide spectrum of neurological and psychiatric disorders. In recent years, substantial progress has been made in the clinical development of small-molecule modulators targeting NMDA receptors. In this review, we summarize recent advances in this rapidly evolving field. Among various therapeutic indications, depression has emerged as an especially active area of investigation, with mechanistically diverse compounds ranging from broad-spectrum channel blockers (ketamine, dextromethorphan, esmethadone) to glycine site modulators (rapastinel, 4-chlorokynurenine, D-cycloserine) and allosteric modulators (apimostinel, zelquistinel), progressing through clinical pipelines. Beyond depression, NMDA receptor-targeted drug discovery is also advancing in other challenging CNS disorders, including neurodegenerative diseases (salzanemdor, NYX-458), pain (NYX-2925), epilepsy (radiprodil), and stroke (nelonemdaz, NP10679). Collectively, these developments reflect the maturation of NMDA receptor pharmacology and reaffirm the broad therapeutic potential of NMDA receptor modulation, while highlighting promising directions for future drug discovery.

01 Jul 2025·PEDIATRIC NEUROLOGY

Current and Emerging Precision Therapies for Developmental and Epileptic Encephalopathies

Review

Author: Keator, Cynthia G ; Nolan, Danielle ; Xiong, Katherine ; Sandoval Karamian, Amanda G ; Bhatia, Sonal ; Schreiber, John M ; Rao, Chethan K ; Sattar, Shifteh ; Samanta, Debopam ; Reeders, Puck C ; Axeen, Erika ; Hunter, Senyene E ; Karakas, Cemal ; Erdemir, Gozde ; Fine, Anthony L

Developmental and epileptic encephalopathies (DEEs) are severe neurological disorders characterized by childhood-onset seizures and significant developmental impairments. Seizures are often refractory to treatment with traditional antiseizure medications, which fail to address the underlying genetic and molecular mechanisms. This comprehensive review explores the evolving landscape of precision therapeutics for DEEs, focusing on mechanism-driven interventions across key pathophysiologic categories. Targeted approaches for channelopathies include antisense oligonucleotides and gene therapies, such as zorevunersen and ETX101 for SCN1A-related Dravet syndrome, alongside novel small molecules for other ion channel disorders. Advances in targeting neurotransmitter receptor dysfunctions, including γ-aminobutyric acid and glutamate receptor variants, highlight the use of modulators such as gaboxadol, radiprodil, and l-serine, alongside emerging gene therapies. For synaptic dysfunctions, innovative treatments such as chemical chaperones for STXBP1-related disorders and Ras-Raf-MEK-ERK inhibitors for SYNGAP1 pathologies are discussed. The review also examines precision interventions targeting cellular signaling pathways in tuberous sclerosis complex, epigenetic regulation in Rett syndrome, and metabolic interventions like ketogenic diets and targeted supplementation for specific genetic etiologies. Additionally, the importance of enhancing access to genetic testing, conducting robust natural history studies, and employing innovative clinical trial designs is emphasized. Future directions focus on addressing the challenges in developing and implementing gene-based therapies, integrating systems biology, leveraging artificial intelligence for data analysis, and fostering collaboration among stakeholders. The rapidly advancing field of precision therapeutics for DEEs holds promise to improve outcomes through tailored, equitable, and patient-centered care.

News (Medical) associated with Radiprodil

05 Aug 2026

·www.prnewswire.com

Neurvati Neurosciences Strengthens Executive Leadership Team to Advance Next Phase of Growth at GRIN Therapeutics

Appointments position GRIN Therapeutics for continued global clinical execution while expanding Neurvati's neuroscience development platform NEW YORK, Aug. 5, 2026 /PRNewswire/ -- Neurvati Neurosciences today announced the appointment of J. Michael Ryan, M.D., as Chief Medical Officer and the promotions of Anne-Marie Li-Kwai-Cheung to Chief Development Officer and Elliott Ruiz to Chief Financial Officer. These leadership appointments come at an important stage for GRIN Therapeutics, Neurvati's founding affiliate company, as it advances the global pivotal Phase 3 Beeline study of investigational radiprodil in GRIN-related neurodevelopmental disorder while continuing the Phase 1b/2a Astroscape study of radiprodil in focal cortical dysplasia type II and tuberous sclerosis complex. Together, these appointments strengthen the executive leadership team responsible for advancing GRIN Therapeutics' clinical programs while positioning Neurvati to continue expanding its neuroscience development platform through future affiliate companies. "GRIN Therapeutics is entering an exciting and important phase as we execute our global Phase 3 program and continue building a company capable of delivering transformative medicines for patients with serious neurological disorders," said Bruce Leuchter, M.D., Chief Executive Officer of Neurvati Neurosciences. "Michael, Anne-Marie, and Elliott each bring exceptional experience, sound judgment, and proven leadership. Together, they create a highly complementary executive team that strengthens our medical, development, and enterprise capabilities – not only for GRIN Therapeutics today, but also as we continue to build Neurvati's long-term neuroscience platform." J. Michael Ryan, M.D., Appointed Chief Medical Officer Dr. Ryan joins Neurvati and GRIN Therapeutics with more than 25 years of neuroscience drug development experience spanning academia, biotechnology, large pharmaceutical companies, and venture-backed organizations. His experience includes leading programs from first-in-human studies through late-stage development across Alzheimer's disease, neurodegenerative disorders, neuropsychiatric diseases, and other central nervous system conditions. Most recently, Dr. Ryan served as Co-Founder and Chief Medical Officer of Aliada Therapeutics, where he led clinical development and regulatory strategy through the company's acquisition by AbbVie. Earlier in his career he held senior leadership roles at Rodin Therapeutics, Asceneuron, RA Capital Management, Novartis, Pfizer, Wyeth, and Merck. As Chief Medical Officer, Dr. Ryan will provide medical and scientific leadership across Neurvati and GRIN Therapeutics, guiding clinical strategy and partnering closely across the enterprise to advance the company's growing neuroscience portfolio. He will play a central leadership role as GRIN Therapeutics advances the Beeline study and continues building its broader development portfolio. "Neurvati has created a distinctive model for bringing new medicines to patients with serious neurological disorders – combining rigorous science, experienced leadership, and long-term strategic capital," said Dr. Ryan. "I am delighted to join GRIN Therapeutics at such an important stage in its development and look forward to working with this talented team to deliver meaningful new therapies for patients and families living with these conditions." Anne-Marie Li-Kwai-Cheung Promoted to Chief Development Officer Anne-Marie Li-Kwai-Cheung's promotion (effective March 2026) recognizes the strong leadership she has demonstrated in preparing GRIN Therapeutics for global Phase 3 execution and reflects the increasing scale and complexity of the company's development activities. Since joining Neurvati, she has been instrumental in providing strategic leadership of the development plan, establishing the capabilities needed to support global product development and the successful initiation of the Beeline study, positioning the company for its next stage of clinical execution. As Chief Development Officer, Li-Kwai-Cheung will continue to lead the advancement of the company's global development programs in close partnership with the Chief Medical Officer, ensuring that clinical strategy is translated into disciplined, high-quality execution across an increasingly complex international portfolio. "Anne-Marie is an outstanding leader for our organization," said Dr. Leuchter. "Her strategic mindset, operational excellence, and ability to bring cross-functional teams together have been instrumental in preparing GRIN Therapeutics for this next phase of growth. This promotion reflects both her significant contributions and the confidence we have in her leadership." Elliott Ruiz Promoted to Chief Financial Officer Elliott Ruiz's promotion reflects the increasingly important leadership role he has assumed across both Neurvati and GRIN Therapeutics. Since joining the company in 2022, he has helped build the financial, operational, and organizational foundation supporting the enterprise while serving as a trusted strategic partner across the leadership team and Board of Directors. As Chief Financial Officer, Ruiz will continue to provide strategic financial and operational leadership across both organizations, helping ensure they are well positioned to execute current clinical programs while pursuing future growth opportunities. "Elliott has helped build Neurvati from its earliest days, and his contributions extend well beyond finance," said Dr. Leuchter. "He is an exceptional enterprise leader whose financial discipline, strategic thinking, and collaborative leadership have strengthened every part of our organization. This promotion recognizes the tremendous impact he has had across both Neurvati and GRIN Therapeutics." About GRIN Therapeutics GRIN Therapeutics, Inc. is dedicated to the research and development of precision therapeutics for neurodevelopmental disorders with the goal of bringing hope to patients and caregivers. In late 2024, GRIN Therapeutics reported promising topline data from a Phase 1b/2a clinical trial (the Honeycomb Trial, ClinicalTrials.gov identifier: NCT05818943) evaluating investigational radiprodil in GRIN-related neurodevelopmental disorder (GRIN-NDD) in patients with gain-of-function (GoF) variants, leading to the decision to advance to the global Phase 3 Beeline trial (ClinicalTrials.gov identifier: NCT07224581). The company has an additional ongoing clinical trial to evaluate radiprodil for the potential treatment of focal cortical dysplasia type II (FCDII) and tuberous sclerosis complex (TSC). GRIN Therapeutics is an affiliate of Neurvati Neurosciences, a portfolio company of Blackstone Life Sciences. For more information, please visit . About Neurvati Neurosciences Neurvati Neurosciences is the neuroscience development platform of Blackstone Life Sciences, created to bridge the gap that has long constrained progress in the field. Neurvati identifies and advances high-potential neuroscience assets through a disciplined, scalable model that establishes and funds fit-for-purpose affiliate companies—each designed to drive development with precision, dedicated capital, and experienced leadership. By addressing the challenges that have historically impeded neuroscience drug development, Neurvati offers a differentiated solution that creates durable value across the neuroscience ecosystem and accelerates the delivery of new therapies for patients with complex neurological and psychiatric disorders. About Blackstone Life Sciences Blackstone Life Sciences is an industry-leading private investment platform with capabilities to invest across the life cycle of companies and products within key life science sectors. By combining scale investments and hands-on operational leadership, Blackstone Life Sciences helps bring to market promising new medicines and medical technologies that improve patients' lives and currently has more than $17 billion in assets under management. Corporate Contact Elliott Ruiz +1 201.674.5417 [email protected] For general inquiries, please reach out to [email protected]. SOURCE Neurvati Neurosciences 21% more press release views with Request a Demo

04 May 2026

·www.prnewswire.com

GRIN Therapeutics' Pivotal Phase 3 Beeline Study Initiated in Europe

European initiation advances global registrational program for investigational radiprodil in GRIN-NDD; initiation augments sites already enrolling in the US and UK NEW YORK, May 4, 2026 /PRNewswire/ -- GRIN Therapeutics, Inc., a leader in the development of targeted, disease-specific therapies for serious neurodevelopmental disorders, today announced the initiation of its pivotal Phase 3 Beeline study in Europe, further advancing its global clinical program evaluating investigational radiprodil for GRIN-related neurodevelopmental disorder (GRIN-NDD). The Phase 3 Beeline trial is a global, registrational study designed to evaluate the efficacy and safety of radiprodil, a selective negative allosteric modulator of the NMDA receptor GluN2B subunit, in patients with GRIN-NDD caused by gain-of-function (GoF) variants. By targeting the underlying biology of NMDA receptor overactivation, radiprodil has the potential to address core aspects of the disease, including seizures, behavioral manifestations, and functional outcomes. "This is an exciting and meaningful milestone for GRIN Therapeutics and, more importantly, for the GRIN-NDD community," said Bruce Leuchter, MD, President and Chief Executive Officer of GRIN Therapeutics. "Expanding the Beeline study into Europe brings us closer to delivering what we hope will be the first targeted, disease-modifying therapy for patients living with this complex and life-altering condition. We are deeply motivated by the families and caregivers who have helped shape this program, and we are committed to advancing radiprodil with urgency, rigor, and a clear focus on making a meaningful difference for patients and their families." The Beeline trial builds on results from the open-label Phase 1b/2a Honeycomb study, which demonstrated encouraging clinical activity and tolerability of radiprodil in patients with GRIN-NDD caused by GoF variants. In that study, patients with countable motor seizures experienced a median reduction of 86% in seizure frequency, and clinicians and caregivers also observed signs of a favorable effect on clinical outcomes regardless of the occurrence of seizures, as measured by Clinician and Caregiver Global Impressions of Change. These data supported the granting of Priority Medicines (PRIME) designation by the European Medicines Agency. The Honeycomb data, together with insights from patients, caregivers, and investigators, informed the design of the Phase 3 program, including a disease-specific endpoint designed to capture behavioral symptoms that clinicians and caregivers consider meaningful, and a cohort that enables enrollment of patients with behavioral symptoms, not requiring countable motor seizures. The initiation of sites in Belgium, France, Germany, Italy, Poland, the Netherlands, Slovenia, and Spain represents the next step in the global expansion of the Beeline trial, which is already enrolling in the United States and the United Kingdom. European activation includes both experienced centers that participated in earlier studies and new clinical sites across multiple countries, supporting efficient study execution and broader patient access. Further EU countries are anticipated to come online in September 2026. The addition of European sites is expected to accelerate progress of the Phase 3 study while expanding access for European patients and families seeking new treatment options. Families can reach out to international groups like GRIN Europe (grineurope.org) and CureGRIN (curegrin.org), or their national advocacy groups, for more information. About Radiprodil Radiprodil is an investigational, potent negative allosteric modulator that selectively targets the GluN2B subunit of the N-methyl-D-aspartate (NMDA) receptor and is being assessed for the treatment of GRIN-related neurodevelopmental disorder (GRIN-NDD). Radiprodil has not been approved for use; its safety and efficacy has not been established. It has been awarded Breakthrough Therapy, Orphan Drug and Rare Pediatric Disease designations by the U.S. Food and Drug Administration as well as Priority Medicines (PRIME) designation by the European Medicines Agency (EMA) and a positive opinion for orphan designation from the EMA Committee for Medicinal Products for Human Use (CHMP). The global Phase 3 Beeline trial for radiprodil in patients with GRIN-NDD gain-of-function variants is designed to evaluate the impact of a targeted disease-specific treatment on core aspects of the disease, including seizures, behavioral manifestations and functional outcomes. Radiprodil is also being assessed for the treatment of tuberous sclerosis complex (TSC) and focal cortical dysplasia (FCD) type II, two disorders associated with NMDA receptor overexpression. The Astroscape trial (ClinicalTrials.gov identifier: NCT06392009) is an ongoing, open-label Phase 1b/2a clinical trial assessing the safety, tolerability, pharmacokinetics (PK), and potential efficacy of radiprodil in patients with TSC or FCD type II. About GRIN Therapeutics GRIN Therapeutics, Inc. is dedicated to the research and development of precision therapeutics for neurodevelopmental disorders with the goal of bringing hope to patients and caregivers. In late 2024, GRIN Therapeutics reported promising topline data from a Phase 1b/2a clinical trial (the Honeycomb Trial, ClinicalTrials.gov identifier: NCT05818943) evaluating investigational radiprodil in GRIN-related neurodevelopmental disorder (GRIN-NDD) in patients with gain-of-function (GoF) variants, leading to the decision to advance to the global pivotal Phase 3 Beeline trial (ClinicalTrials.gov identifier: NCT07224581). The company has an additional ongoing clinical trial to evaluate radiprodil for the potential treatment of focal cortical dysplasia type II (FCDII) and tuberous sclerosis complex (TSC). GRIN Therapeutics is an affiliate of Neurvati Neurosciences, a portfolio company of Blackstone Life Sciences. For more information, please visit . About Neurvati Neurosciences Neurvati Neurosciences is the neuroscience development platform of Blackstone Life Sciences, created to bridge the gap that has long constrained progress in the field. Neurvati identifies and advances high-potential neuroscience assets through a disciplined, scalable model that establishes and funds fit-for-purpose affiliate companies—each designed to drive development with precision, dedicated capital, and experienced leadership. By addressing the challenges that have historically impeded neuroscience drug development, Neurvati offers a differentiated solution that creates durable value across the neuroscience ecosystem and accelerates the delivery of new therapies for patients with complex neurological and psychiatric disorders. About Blackstone Life Sciences Blackstone Life Sciences is an industry-leading private investment platform with capabilities to invest across the life cycle of companies and products within key life science sectors. By combining scale investments and hands-on operational leadership, Blackstone Life Sciences helps bring to market promising new medicines and medical technologies that improve patients' lives and currently has more than $17 billion in assets under management. Corporate Contact Elliott Ruiz +1 201.674.5417 [email protected] For general inquiries, please reach out to [email protected]. SOURCE GRIN Therapeutics Inc. 21% more press release views with Request a Demo

Phase 3Orphan DrugBreakthrough TherapyClinical Result

01 May 2026

·endpoints.news

Boehringer appoints pharma veteran for corporate affairs post; BlueRock CSO heads for the exit

→ Boehringer Ingelheim has brought in Christie Bloomquist as SVP, corporate affairs, US human pharma, and she’ll be president of the Boehringer Cares Foundation. Peer Review informed you about her move to Astellas in 2023, and she had been VP, US strategy and government affairs at the Japanese drugmaker since January 2025. She was also in charge of US corporate and government affairs at AstraZeneca . “What drew me in was how both comfortable and challenged I felt with everyone I met during the interview process,” Bloomquist wrote in a LinkedIn post . “These are people I genuinely want to work with, in a place where I know I can contribute.” → In another LinkedIn discovery, Stefan Irion is stepping down as CSO of Bayer ’s BlueRock Therapeutics . Irion was promoted to this position in 2023 and started working at BlueRock “in its earliest days, when the idea was audacious and the roadmap mostly lived on whiteboards and in late‑night conversations,” he wrote . BlueRock has moved into Phase 3 with bemdaneprocel , a cell therapy to treat Parkinson’s disease. → Not only did Incyte get a pair of Phase 3 wins in nonsegmental vitiligo this week, its search for a CFO is over . Suky Upadhyay replaced Dan Florin as CFO of Zimmer Biomet in 2019 and would tack on the role of EVP, global operations. Upadhyay is currently on the board of directors at Vertex and led global financial operations at Bristol Myers Squibb from 2016-19. You may recall that Christiana Stamoulis left Incyte in September to become CFO at Mallinckrodt , which is now known as Keenova after the merger with Endo . Zimmer Biomet said that Paul Stellato will fill in as interim finance chief. → Shortly before landing on the Nasdaq in a $255 million IPO this week, Seaport Therapeutics snagged neuroscience veteran Sharon Mates for its board. The mid-stage neuroscience biotech now has the former chair and CEO of Intra-Cellular Therapies to help guide it toward commercialization. Mates led Intra-Cellular all the way from the ground up, put it on a commercial footing, and took it to a $14.6 billion exit to Johnson & Johnson . → Jennifer Smoter said in a LinkedIn post that she’s “thrilled to return to the biopharmaceutical industry” as chief communications & governance officer at Takeda . Smoter led the communications team during her four and a half years with UnitedHealth Group , and she was chief external affairs & communications officer at Intellia Therapeutics . As part of its multiyear restructuring , Takeda recently ended its partnership with Denali Therapeutics . The Japanese pharma reports its FY2025 earnings on May 13. → A spokesperson tells Peer Review that AI-focused startup Basecamp Research has tapped Richard Pearce as CBO after raising the curtain on its Trillion Gene Atlas project last month. Basecamp plucked him from Biogen , where he was head of business development, strategy and portfolio management in the back half of his 11-year career with the company. Earlier, Pearce served as business and operations director of the Biodevelopment Centre at Merck KGaA . “By training foundation models on the largest evolutionary dataset ever assembled, Basecamp is building something fundamentally new for biology,” Basecamp CEO Glen Gowers said in a statement. “Richard brings a rare combination of deep pharma experience and first-principles thinking — exactly what’s needed to translate this technology into real-world impact.” → Boston-based mRNA startup Strand Therapeutics has hired its first-ever CFO. Kunal Bhatia started his career at Credit Suisse and Jefferies , and has been a managing director in the healthcare investment banking groups at Oppenheimer and TD Cowen . Kinnevik , Regeneron Ventures , Amgen Ventures and Eli Lilly participated in Strand’s $153 million Series B last summer. → Coy Stout is retiring after 30 years in industry, with the last year and a half as executive director of US patient support at AstraZeneca. He’s had stops along the way at Lykos , Brii Biosciences and nearly two decades at Gilead . “While I expected this part of my journey as a market access leader to last a little bit longer,” Stout wrote on LinkedIn, “life has a way of making priorities clear. I’m stepping away from the industry to focus on work-life balance and on one of the most important roles of my life: being a spouse and caregiver to someone living with advancing Parkinson’s disease.” → Now under the direction of ex- bluebird bio boss Andrew Obenshain , Inventiva has welcomed three new execs, including former CureVac finance chief Axel-Sven Malkomes . He’ll be the first person besides Jean Volatier to step into the CFO slot in the company’s history, and Volatier will still have a presence at Inventiva as EVP of finance & corporate social responsibility. Meanwhile, Inventiva has recruited Susan Coles as chief legal officer and Pamela Herbster as chief people officer. Coles has already been general counsel at Inventiva twice, and Herbster was elevated to chief people & experience officer at Sage before Supernus bought the embattled drug developer for $561 million. → Newly public Avalyn Pharma has recruited Adam Golden as general counsel and head of business development, and Frank Salisbury as SVP of commercial. Golden comes to Avalyn from London-based law firm Freshfields , where he was a partner and global head of life sciences. Salisbury is a Sage and Genentech alum who spent the last four years with PureTech Health as head of commercial and product strategy. → Lis Leiderman has returned to Peer Review for her fourth CFO job this decade. Her LinkedIn page indicates that she succeeded Rob Lauzen at Dutch neuro biotech Prilenia Therapeutics in March. Leiderman worked for Decibel Therapeutics (2020-22), Atsena Therapeutics (2022-23) and Dewpoint Therapeutics (2024-25), and she sits on the board of directors at Autolus Therapeutics . Prilenia’s only candidate is an S1R agonist called pridopidine for ALS and Huntington’s disease. → Sanofi Genzyme vet Michael Panzara has replaced co-founder Andreas Muehler as CMO of Immunic . Panzara had been CMO of Blackstone ’s Neurvati Neurosciences and its subsidiary GRIN Therapeutics , which collected $50 million upfront from Angelini Pharma for the ex-North America rights to radiprodil . He also vaulted to CMO and head of therapeutics discovery & development during a six-year run at Wave Life Sciences . → Radiotherapy shop Convergent Therapeutics has selected Merck vet Andrew Davis as chief business and strategy officer. Davis concluded his stint as CBO of Dynavax after it was purchased by Sanofi for $2.2 billion, and he held that same role at Ironwood Pharmaceuticals . → Christian Schade has been named chairman of the board at German biotech CatalYm . Since selling Halda Therapeutics to J&J for north of $3 billion last fall, Schade joined Frazier Life Sciences as a senior advisor. After a stint as CEO of Aprea Therapeutics , he landed at Flagship Pioneering in early 2023 as a growth partner. → Marea Therapeutics CEO Josh Lehrer has locked up a spot on the board of directors at Fulcrum Therapeutics . With a series of roles over a six-year period at Global Blood Therapeutics , including CMO, his input on Fulcrum’s lead sickle cell asset pociredir should be beneficial. Lehrer ran Graphite Bio until it merged with Lenz Therapeutics . → Deborah Birx ’s bacteriophage biotech Armata Pharmaceuticals has appointed Daniel Gilmer to its board of directors. Gilmer was elevated to senior director, commercial quality US team lead at Pfizer last year. → In other boardrooms, Raymond Dwek will retire at United Therapeutics , but he’ll stay on the scientific advisory board; Boehringer Ingelheim’s Lykke Hinsch Gylvin is headed to ProQR ; Troy Cox and Alumis CEO Martin Babler are in line to replace Robert Malenka and Jim Trenkle at Maplight Therapeutics , according to an SEC filing ; Santhera has added ex- Idorsia CEO Srishti Gupta ; and InduPro Therapeutics CEO Prakash Raman has picked up a board seat at Olema Oncology .

Executive ChangeIPOPhase 3

100 Deals associated with Radiprodil

External Link

KEGG	Wiki	ATC	Drug Bank
D13319	-	-	DB12260

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Myasthenic Syndromes, Congenital	Phase 3	United States	GRIN Therapeutics, Inc.	01 Jun 2026
Myasthenic Syndromes, Congenital	Phase 3	Japan	GRIN Therapeutics, Inc.	01 Jun 2026
Myasthenic Syndromes, Congenital	Phase 3	Australia	GRIN Therapeutics, Inc.	01 Jun 2026
Myasthenic Syndromes, Congenital	Phase 3	Belgium	GRIN Therapeutics, Inc.	01 Jun 2026
Myasthenic Syndromes, Congenital	Phase 3	Canada	GRIN Therapeutics, Inc.	01 Jun 2026
Myasthenic Syndromes, Congenital	Phase 3	France	GRIN Therapeutics, Inc.	01 Jun 2026
Myasthenic Syndromes, Congenital	Phase 3	Germany	GRIN Therapeutics, Inc.	01 Jun 2026
Myasthenic Syndromes, Congenital	Phase 3	Italy	GRIN Therapeutics, Inc.	01 Jun 2026
Myasthenic Syndromes, Congenital	Phase 3	Netherlands	GRIN Therapeutics, Inc.	01 Jun 2026
Myasthenic Syndromes, Congenital	Phase 3	Poland	GRIN Therapeutics, Inc.	01 Jun 2026

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT06392009 (Astroscope, IEC2025)	Phase 1/2	Focal Cortical Dysplasia of Taylor \| Tuberous Sclerosis	30	Radiprodil (Focal cortical dysplasia type II + Tuberous sclerosis complex)	wvitmamxhl(hzyrkrfkcl) = jftaijthjp zhjpevjmul (uaoclujfmb )	Positive	30 Aug 2025
NCT02647697 (Pubmed \| Pharmacol Res Perspect)	Phase 1	-	10	Radiprodil oral suspension	rajfuloxlk(cscfbxsawl) = afffgirwqj wbyhshpnfu (gdapghgppy ) View more	-	01 Feb 2019

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis